{
    "clinical_study": {
        "@rank": "16605", 
        "acronym": "HEIGHTEN", 
        "arm_group": [
            {
                "arm_group_label": "Non-HPR group", 
                "arm_group_type": "No Intervention", 
                "description": "The non-HPR group will have PD and genetic testing, with no change in medication."
            }, 
            {
                "arm_group_label": "HPR Group", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg\n      LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who\n      exhibit high-on prasugrel platelet reactivity defined as Vasodilator Stimulated\n      Phosphoprotein-Phosphorylation (VASP-P) >50%."
        }, 
        "brief_title": "Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor", 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female; age \u2265 18 and < 75 years\n\n          2. Weight \u2265 60 kg\n\n          3. Currently on ASA therapy and eligible to reduce ASA dose to 81 mg daily if on higher\n             dosing\n\n          4. On stable prasugrel maintenance dose for \u22651 month\n\n          5. Stable CAD patients defined as: subjects with documented evidence of a history of\n             atherosclerotic coronary artery disease/surgical revascularization (defined as either\n             a prior myocardial infarction, percutaneous coronary intervention or coronary artery\n             bypass graft surgery). A minimum of 1 month must have elapsed between a subject's\n             enrolment and any acute event, revascularization procedure or hospitalization for\n             chest pain for that subject.\n\n          6. If female, may be enrolled if one of the following 3 criteria are met: 1)Had a\n             hysterectomy or tubal ligation at least 6 months prior to signing ICF,\n             2)Post-menopausal for at least 1 year, 3)If of childbearing potential, will practice\n             1 of the following methods of birth control throughout the study: oral, injectable,\n             or implantable hormonal contraceptives; intrauterine device; diaphragm plus\n             spermicide; or female condom plus spermicide. Methods of contraception that are not\n             acceptable are partner's use of condoms or partner's vasectomy.\n\n          7. Able and willing to provide written informed consent before entering the study\n\n        Exclusion Criteria:\n\n          1. Subject plans to undergo coronary revascularization at any time during the trial\n\n          2. Presence or history of any of the following: ischemic or hemorrhagic stroke;\n             transient ischemic attack (TIA); intracranial neoplasm; arteriovenous malformation,\n             or aneurysm; intracranial hemorrhage; head trauma (within 3 months of study entry)\n\n          3. History of refractory ventricular arrhythmias with an increased risk of bradycardic\n             events (eg, subjects without a pacemaker who have sick sinus syndrome, 2nd or 3rd\n             degree atrioventricular (AV) block or bradycardic-related syncope)\n\n          4. History or evidence of congestive heart failure (New York Heart Association Class III\n             or above  \u2264 6 months before screening\n\n          5. Severe hepatic impairment defined as ALT> 2.5 X ULN\n\n          6. Uncontrolled hypertension, or systolic blood pressure > 180 mmHg or diastolic blood\n             pressure > 110 mmHg at screening\n\n          7. Severely impaired renal function (glomerular filtration rate < 30 mL/minute) or on\n             dialysis\n\n          8. Concomitant use with parenteral or oral anticoagulants\n\n          9. Platelet count <100 X103"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869309", 
            "org_study_id": "2015", 
            "secondary_id": "ISSBRIL0149"
        }, 
        "intervention": [
            {
                "arm_group_label": "HPR Group", 
                "description": "Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.", 
                "intervention_name": "Prasugrel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HPR Group", 
                "description": "Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).", 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Platelet Aggregation Inhibitors", 
                "Prasugrel", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Coronary artery disease", 
            "anti-platelet medications", 
            "Platelet-aggregation Inhibitors"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "kbliden@lifebridgehealth.org", 
                "last_name": "Kevin P Bliden, BS, MBA", 
                "phone": "410-601-4795"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21215"
                }, 
                "name": "Sinai Center for Thrombosis Research"
            }, 
            "investigator": {
                "last_name": "Paul A Gurbel, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy", 
        "other_outcome": {
            "description": "To evaluate the safety and tolerability of switching subjects from Prasugrel to Ticagrelor and vice versa.", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "14 days, 28 days"
        }, 
        "overall_contact": {
            "email": "kbliden@lifebridgehealth.org", 
            "last_name": "Kevin P Bliden, BS, MBA", 
            "phone": "4106014795"
        }, 
        "overall_official": {
            "affiliation": "LifeBridge Health", 
            "last_name": "Paul A Gurbel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable CAD patients who exhibit high-on prasugrel platelet reactivity defined as VASP-P>50%.", 
            "measure": "Pharmacodynamic (PD) Vasodilator Stimulated Phosphoprotein-Phosphorylation(VASP-P) in High On Prasugrel Platelet Reactivity(HPPR) stable CAD patients", 
            "safety_issue": "No", 
            "time_frame": "2 hours, 4 hours, and 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the prevalence of HPPR in a stable PCI population.", 
                "measure": "Prevalence of HPPR", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 4 hours, and 14 days"
            }, 
            {
                "description": "Determine the relation of CYP2C19 activity to the occurrence of HPPR.", 
                "measure": "CYP2C19 relation to occurence of HPPR", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 4 hours, and 14 days"
            }, 
            {
                "description": "Evaluate the PD effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable CAD patients who exhibit HPPR defined as  PRU >208 by VerifyNow P2Y12", 
                "measure": "PD VerifyNow in HPPR stable CAD patients", 
                "safety_issue": "No", 
                "time_frame": "2 hour, 4 hour, 14 days"
            }, 
            {
                "description": "Evaluate the PD effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable CAD patients who exhibit HPPR  based on light  transmittance aggregometry (5 and 20 uM ADP,  4ug/mL Collagen)", 
                "measure": "PD LTA in HPPR stable CAD patients", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 4 hours, 14 days"
            }, 
            {
                "description": "To determine the frequency of HPR after switching from ticagrelor to prasugrel after 14 days of treatment.", 
                "measure": "Frequency of HPR", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 4 hours, and 14 days"
            }, 
            {
                "description": "To determine if the PD effect of prasugrel is related to the activity of CYP2C19 (phenotyping and genotyping) by measuring patients with and without HPPR.", 
                "measure": "PD effect(Prasugrel) relation to CYP2C19", 
                "safety_issue": "No", 
                "time_frame": "2 hours, 4 hours, and 14 days"
            }
        ], 
        "source": "LifeBridge Health", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "LifeBridge Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}